Tradestie Institutional Equity Comparison Engine
CELU vs FBRX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FBRX Overall Edge
FBRX Captures Institutional Edge (3โ0 Pillars ยท 8โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Forte Biosciences, Inc. Common Stock (FBRX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CELU trades at N/M Forward P/E with -254.0% operating margin (-5.3% YoY revenue) versus FBRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CELU sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro) against FBRX sits in UNCLASSIFIED (3rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CELU N/M vs FBRX N/M Fwd P/E
Growth & Margin Winner
FBRX
Op Margin -254.0% vs 0.0% ยท YoY -5.3% vs +0.0%
Momentum & Technical Winner
FBRX
1Y -72.6% vs +580.4% ยท 52W Pos 2% vs 100%
Options & Structure Winner
FBRX
BREAKDOWN (50th %ile IV) vs UNCLASSIFIED (3rd %ile IV)
CELU
NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap
$15.2M
1M Return
-55.9%
1Y Return
-72.6%
Forward P/E
N/M
Unified AI Score
42.9 / 100
HOLD
Tech 25.0
Fund 48.0
Flow 67.0
Mom 55.0
FBRX
NASDAQ
Forte Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$76.99
+0.03% 1D
Market Cap
$1.6B
1M Return
+0.44%
1Y Return
+580.42%
Forward P/E
N/M
Unified AI Score
52.7 / 100
HOLD
Tech 49.0
Fund 51.0
Flow 62.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CELU -72.6%
FBRX +580.42%
Spread: +359.4 pp (FBRX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CELU Revenue | FBRX Revenue | CELU Op. Margin | FBRX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $20M | N/A | -254.2% | FBRX |
| FY2019 | N/A | $0M | N/A | -11288.9% | FBRX |
| FY2020 | $10M | N/A | -1064.0% | N/A | CELU |
| FY2021 | $20M | N/A | -511.2% | N/A | CELU |
| FY2022 | $20M | N/A | -142.4% | N/A | CELU |
| FY2023 | $20M | N/A | -844.4% | N/A | CELU |
| FY2024 | $50M | N/A | -70.7% | N/A | CELU |
| FY2025 | $30M | N/A | -230.9% | N/A | CELU |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CELU | FBRX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.2M | $1.6B | Larger Scale | FBRX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -5.3% | +0.0% | Higher Growth | FBRX |
| Operating Margin (TTM) Profitability | -254.0% | 0.0% | Higher Margin | FBRX |
| Net Profit Margin Profitability | -245.7% | 0.0% | Higher Margin | FBRX |
| Return on Equity (ROE) Capital Efficiency | -6367.2% | -62.3% | Higher ROE | FBRX |
| 52-Week Range Position Momentum | 2% ($0โ$3) | 100% ($10โ$77) | Stronger Trend | FBRX |
| Beta / 30D Volatility Risk Regime | 2.01ฮฒ ยท 135% Vol | 1.09ฮฒ ยท 3% Vol | Lower Realized Risk | FBRX |
| Unified Institutional Score Composite Signal | 42.9 / 100 (HOLD) | 52.7 / 100 (HOLD) | Higher Composite | FBRX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CELU vs FBRX Buy Guide
CELU
BREAKDOWN
60d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
50th %ile
IV Regime
Balanced (25thโ60th %ile)
FBRX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
3rd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CELU nor FBRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.